The company reported results from the P-II study evaluating the efficacy of QL1706 + CT with/without bevacizumab for the treatment of patients (n=91) with EGFR wild-type and mutant advanced NSCLC
The results showed that QL1706 + CT with/without bevacizumab demonstrated effective treatment for advanced NSCLC. In EGFR wild-type NSCLC patients, the ORR was 45%, mPFS was 6.8mos., median iDOR was 11.5mos., and mDOR was not attained
Moreover, QL1706 + CT & bevacizumab demonstrated an ORR of 54.8% and mPFS of 8.5mos. in EGFR-mutant NSCLC patients who progressed after EGFR-TKI therapy suggesting its potential over PD-1 inhibitor combined with CT and bevacizumab
Ref: PRNewswire | Image: Qilu Pharmaceutical
Related News:- Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
